Home > Result Summaries: Compounds > H5N1 Pandemic Influenza Vaccine

Result Summaries: H5N1 Pandemic Influenza Vaccine

Result Summaries for H5N1 Pandemic Influenza Vaccine
GSK
Study ID		 Phase Title Summary (Download)
106750 Phase 1 Observer-blind monocentric study in adults aged b/w 18-60 yrs to evaluate reactogenicity and immunogenicity of 1 and 2 administrations of pandemic monovalent influenza vaccines administered at different antigen doses & adjuvanted or not. (2 citation(s)) Click here to download result summary.
107066 Phase 2 Controlled study of safety & immunogenicity of diff. antigen doses of a pandemic influenza vaccine candidate (GSK1562902A) given as 2 doses in children between 3 & 9 yrs of age. (0 citation(s)) Click here to download result summary.
107495 Phase 2 Reactogenicity and Immunogenicity Study of GlaxoSmithKline Biologicals Pandemic Influenza Vaccine (GSK1119711A) Administered According to Different Vaccination Schedules (1 citation(s)) Click here to download result summary.
108251 Phase 2 Evaluate immunogenicity & safety of a single or double-dose of the pandemic influenza candidate vaccine (GSK1562902A) given following a two-administration schedule (21 days apart) in adults over 60 yrs (0 citation(s)) Click here to download result summary.
109630 Phase 3 Assess the consistency of the immunogenicity of a GlaxoSmithKline Biologicals' pandemic influenza vaccine (GSK1562902A) in adults aged between 18 and 60 years. (1 citation(s)) Click here to download result summary.
109817 Phase 2 Evaluate the reactogenicity & immunogenicity of 1 or 2 booster administrations of an influenza pandemic candidate vaccine (GSK1562902A) in primed adults aged between 19 & 61 years (2 citation(s)) Click here to download result summary.
110028 Phase 1 A Phase I/II, Observer-Blind, Randomized, Active-Controlled Trial to Evaluate the Safety and Immunogenicity of a Two-Dose Series of GSK Biologicals' Candidate Influenza Vaccine GSK 1557484A Antigens With or Without Adjuvant (0 citation(s)) Click here to download result summary.
110464 Phase 3 A trial to evaluate the safety and immunogenicity of an investigational vaccination regimen in adults aged ≥18 years (1 citation(s)) Click here to download result summary.
111443 Phase 3 Immunogenicity of GSK Biologicals’ pandemic influenza vaccine (GSK1562902A) at different boosting vaccination schedules (0 citation(s)) Click here to download result summary.
111954 Phase 3 Non-inferiority study of GSK Biologicals’ Pandemic influenza vaccine 1562902A. (0 citation(s)) Click here to download result summary.

Filter list by: